|
 "There is still room for improvement. But that will ultimately also
depend on demand," Poetting said in an interview with the
Handelsblatt newspaper published on Wednesday.
Poetting said if premises were available, BioNtech could build up
additional production capacity in six months, adding that
discussions were ongoing.
"We have a lot of inquiries," the CFO said.
The Mainz-based biotech company and its U.S. partner Pfizer plan to
produce 2.5 billion COVID-19 doses this year, of which 1.4 billion
were already sold. The companies aim to raise production to three
billion shots in 2022.
[to top of second column] |
 BioNTech in February launched
production at its new site in the city of
Marburg, which it purchased from Novartis last
year, raising its annual capacity by around 1
billion doses.
(Reporting by Riham Alkousaa; editing by Jason
Neely)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
